DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-refractory lung adenocarcinoma (LUAD) progression is a major clinical problem. New approaches to predict and prevent acquired resistance to EGFR TKIs are urgently needed. Here, we show that dopamine and cyclic AMP-regulated phos...

Descripción completa

Detalles Bibliográficos
Autores principales: Alam, Sk. Kayum, Zhang, Yongchang, Wang, Li, Zhu, Zhu, Hernandez, Christina E., Zhou, Yuling, Yang, Nong, Lei, Jian, Chen, Xiaoyan, Zeng, Liang, Klein, Mark A., Hoeppner, Luke H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529229/
https://www.ncbi.nlm.nih.gov/pubmed/34675407
http://dx.doi.org/10.1038/s41388-021-02028-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529229/
https://www.ncbi.nlm.nih.gov/pubmed/34675407
http://dx.doi.org/10.1038/s41388-021-02028-5

Ejemplares similares